Latest News and Press Releases

Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan’s MHLW ASHBURN,...

Asimov will provide technologies for cell line development and process development to researchers at the Goodman Cancer Institute.

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of...

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative...

The Swiss Deep Tech Report 2026 ranks Switzerland first in the world for the share of venture capital going to deep tech, ahead of China and the US

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...

Oncolytics Biotech announced that the USPTO has issued a new patent broadly protecting the proprietary manufacturing process for pelareorep into 2044.

AmMax Bio, clinical stage targeted oncology ADC company, names biopharmaceutical Executive Travis Read as President and COO.

Pluristyx issued Japan patent allowance for next-gen synthetic mRNA, accelerating non-viral, footprint-free iPSC generation for regenerative medicine

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.